Literature DB >> 19027226

Naturally-occurring shikonin analogues--a class of necroptotic inducers that circumvent cancer drug resistance.

Yanyan Xuan1, Xun Hu.   

Abstract

We previously reported that shikonin could circumvent drug resistance mediated by P-gp, Bcl-2 and Bcl-xL, by induction of necroptosis. Here, we show that the naturally-occurring shikonin analogues (deoxyshikonin, acetylshikonin, isobutyrylshikonin, beta,beta-dimethylacrylshikonin, isovalerylshikonin, alpha-methyl-n-butylshikonin) could bypass drug resistance mediated by not only P-gp, Bcl-2, and Bcl-xL, but also two additional important drug-resistant factors MRP1 and BCRP1, by induction of necroptosis. The results strengthen the previous findings that necroptotic induction could circumvent a broad spectrum of cancer drug resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027226     DOI: 10.1016/j.canlet.2008.09.029

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  37 in total

Review 1.  Targeting Cancer Metabolism and Current Anti-Cancer Drugs.

Authors:  Witchuda Sukjoi; Jarunya Ngamkham; Paul V Attwood; Sarawut Jitrapakdee
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Relevance of necroptosis in cancer.

Authors:  Najoua Lalaoui; Gabriela Brumatti
Journal:  Immunol Cell Biol       Date:  2016-12-06       Impact factor: 5.126

3.  Shikonin enhances Adriamycin antitumor effects by inhibiting efflux pumps in A549 cells.

Authors:  Xuchun Liu; Gengyun Sun
Journal:  Oncol Lett       Date:  2017-08-02       Impact factor: 2.967

4.  β, β-Dimethylacrylshikonin induces mitochondria-dependent apoptosis of human lung adenocarcinoma cells in vitro via p38 pathway activation.

Authors:  Hai-bing Wang; Xiao-qiong Ma
Journal:  Acta Pharmacol Sin       Date:  2014-12-01       Impact factor: 6.150

5.  PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells.

Authors:  Wenjuan Li; Joan Liu; Yunfeng Zhao
Journal:  Mol Carcinog       Date:  2012-12-19       Impact factor: 4.784

6.  In vitro and in vivo antitumor effects of acetylshikonin isolated from Arnebia euchroma (Royle) Johnst (Ruanzicao) cell suspension cultures.

Authors:  Wenbi Xiong; Gang Luo; Liming Zhou; Yun Zeng; Wenji Yang
Journal:  Chin Med       Date:  2009-07-11       Impact factor: 5.455

Review 7.  The Microenvironment of Tongue Cancer.

Authors:  Want Tao; Zeng Li-Juan; Li Kan; Li Jing-Yuan; Liu Xiang-Qi; Liang Yu-Jie
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

8.  Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer.

Authors:  Jens C Hahne; Heike Schmidt; Susanne R Meyer; Jörg B Engel; Johannes Dietl; Arnd Honig
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-26       Impact factor: 4.553

9.  Shikonin inhibits myeloid differentiation protein 2 to prevent LPS-induced acute lung injury.

Authors:  Yali Zhang; Tingting Xu; Zheer Pan; Xiangting Ge; Chuchu Sun; Chun Lu; Hongjin Chen; Zhongxiang Xiao; Bing Zhang; Yuanrong Dai; Guang Liang
Journal:  Br J Pharmacol       Date:  2018-01-25       Impact factor: 8.739

10.  Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment.

Authors:  Qiang Wang; Jing Wang; Jiayou Wang; Xiaoli Ju; Heng Zhang
Journal:  Toxicol Res (Camb)       Date:  2021-11-26       Impact factor: 3.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.